PFEPfizerRunning, no new patients
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Hormone Sensitive Prostate Cancer · Prostate Cancer · Cancer of the Prostate
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 1,068 (final count)
- Started
- Dec 17, 2014
- Main results expected
- Jan 31, 2023
- Fully finished
- Jul 30, 2027
- Results posted
- Mar 25, 2024
What counts as success
The trial's main goal(s), called the “primary outcome.”
Metastasis-free Survival (MFS) Compared Between Enzalutamide Plus Leuprolide and Placebo Plus Leuprolide
Measured over: From randomization until radiographic progression or death without radiographic progression, whichever occurred first (up to Month 98 when at least 197 MFS events occurred among the 3 treatment groups)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT02319837 · record last updated 2026-10-26 · checked 2026-11-09 15:47 UTC